DPHARMA | DUOPHARMA BIOTECH BHD

1.48 (-4.52%)
4

T-O: 0.0 (08:59:00)
Last updated: 17:00

Fundamental
Technical
Total Score

DPHARMA | DUOPHARMA BIOTECH BHD

iSaham Fundamental Trend

FCON: | Sharpe Ratio: | LTS:


Quarter Reports

Chart:

Trailing Dividend

Financial Ratios

EPS7.03 sen
Trailing PE (Sector Median: 18.1)21.1
PEG0.51
Altman Z1.3
Beaver-0.008
Current Ratio2.11
Debt-Equity (DE) Ratio0.93
FCF Yield-7.51 %
Revenue QoQ28.46 %
Revenue YoY9.46 %
Profit QoQ20.08 %
Profit YoY21.51 %
Profit Margin (Sector Median: 3.6)10.54 %
ROE (ROIC: 7.25)10.8 %
Dividend Per Share (DPS)6.5 sen
Dividend Yield (DY)4.39 %

Fair Value

Weighted Average Fair Value:

Discounted Cash Flow (DCF) 5% Growth
Discounted Cash Flow (DCF) 10% Growth
Relative Valuation
Average Analysts FV based on 4 rating(s)
Graham Formula
Graham Number
Net Tangible Asset (NTA)0.65
Consistent QR FV
The Fair Value numbers are not, and must not be construed to be, any recommendation, offer or invitation to buy or sell any securities, futures contracts or any other instrument. The figures shown here should be taken as educational purposes only

Advanced Calculators

Calculate the fair value of the stock based on expected growth / risk, contract / award value, forecasted profit or forecasted revenue.

Forward PE FV Calculator
Latest Profit (adjusted) [M]15.85
Expected Profit (Next QR) [M]
Expected Profit (After QR above) [M]
Expected Profit (After QR above) [M]
Estimated Fair Value
Growth/Risk Fair Value Calculator
Expected growth (%)
Estimated downside / risk (%)
Estimated New DCF Fair Value
Contract/Award Contribution Calculator
Contract/Award Value (in Million)
Estimated Contribution to Stock Price
Estimated New DCF Fair Value
Profit-Based Calculator
Expected Profit (M)
for Year
Estimated New DCF Fair Value
Revenue-Based Calculator
Expected Revenue (M)
for Year
Estimated New DCF Fair Value
Market Pricing
Expected Profit (M)461.63
Expected Revenue (M)4254.63
Expected Growth (%)31.0
The Fair Value calculated using this calculators are not, and must not be construed to be, any recommendation, offer or invitation to buy or sell any securities, futures contracts or any other instrument. The purpose of this tool is to help investor to quickly calculate their own expected Fair Value based on their own research

Directors Share Purchases (Beta)


No transaction in the last 2 months.

Summary


Market Cap: 1393 M.

Number of Shares: 941 M.

Adjusted Float: 40.43%.

Stock highly correlated with

GIIB (84%)

HEALTH CARE (84%)

DGSB (83%)

LIIHEN (83%)

Duopharma core competencies in the pharmaceutical industry include manufacturing, research and development, and commercialization and marketing of over 300 generic drugs, including Omesec and Prelica, as well as Consumer Healthcare (CHC) products such as CHAMPS, FLAVETTES, PROVITON, and Uphamol, which are well-known and accepted by consumers in Malaysia, the region, and around the world. With technological and commercialization agreements with trustworthy and powerful international partners, the Company has also ventured into the biosimilars space.Their headquarters is located in Kuala Lumpur, Malaysia.

Sectors: Consumer Products, Healthcare, Pharmaceuticals, Technology, Post MCO, Vaccine, Small Cap

Code: 7148

Website: http://duopharmabiotech.com/

Related Links: Bursa | Annual Report | Announcement

Top Shareholdings

Updated on 25-Mar-2020

ShareholderValue (M)
Permodalan Nasional Berhad469.93
Employees Provident Fund Board84.58
Amanah Saham Bumiputera44.4
Billion Victory Sdn Bhd25.28
Public Islamic Treasures Growth Fund10.67
Norges Bank10.06
Manulife Investment Shariah Progressfund9.99
Kumpulan Wang Persaraan (Diperbadankan)7.56
Principal Dali Opportunities Fund6.84
Eastspring Investmentssmall-Cap Fund6.21
Manulife Investment Progress Fund6.21
Lembaga Tabung Haji5.95
Affin Hwang Aiiman Asia (Ex Japan) Growth Fund4.98
Amanah Saham Malaysia 34.61
Tokio Marine Life Insurance Malaysia Bhd4.19
Principal Islamic Small Cap Opportunities Fund4.04
Affin Hwang Growth Fund3.6
Ooi Keng Tan3.26
CIMB-Principal Small Cap Fund3.17
Petroliam Nasional Berhad3.12
Gibraltar BSN Aggressive Fund2.94
Affin Hwang Principled Growth Fund2.93
Medical Fund2.74
Credit Suisse2.74
Amtotal Return2.61
Hong Leong Assurance Berhad2.55
Areca Equitytrust Fund2.44

This calculator use Malacca Securities (M+) cash upfront rate (min RM 8 or 0.08%) for all brokerage fee calculation.
This calculator use Malacca Securities (M+) cash upfront rate (min RM 8 or 0.08%) for all brokerage fee calculation.